Dr. Michael Davidson is a distinguished cardiologist and industry leader who currently serves as Chief Executive Officer and Executive Board member of NewAmsterdam Pharma, a position he has held since August 2020. Previously, he was the founding CEO and Chief Medical Officer of Corvidia Therapeutics, which was acquired by Novo-Nordisk in 2020, and co-founded Omthera Pharmaceuticals, later acquired by AstraZeneca. Dr. Davidson maintains his clinical expertise as a Clinical Professor and Director of the Lipid Clinic at the University of Chicago Pritzker School of Medicine, where he has significantly contributed to patient care and medical education. Board-certified in internal medicine, cardiology, and clinical lipidology, he previously served as President of the National Lipid Association from 2010 to 2011. He received his BA/MS from Northwestern University and MD from The Ohio State University School of Medicine, establishing the foundation for his distinguished career at the intersection of clinical medicine and pharmaceutical development.
Dr. Davidson is internationally recognized as a leading expert in lipidology research with extensive contributions to the understanding and treatment of cardiovascular disease. His research spans over 1,000 clinical studies focusing on statins, novel lipid-lowering drugs, and omega-3 fatty acids, significantly advancing the field of cardiovascular therapeutics. His work has been instrumental in establishing the critical relationship between elevated LDL-C levels and atherosclerosis, the underlying process that leads to cardiovascular disease. For fifteen consecutive years, he has been named to The Best Doctors in America list, reflecting his exceptional clinical expertise and contributions to patient care. His scholarly output includes numerous publications in prestigious journals, with recent work focusing on population pharmacokinetic-pharmacodynamic frameworks for dyslipidemia treatment and cardiovascular pharmacology.
Beyond his research contributions, Dr. Davidson has played pivotal roles in the development and commercialization of multiple blockbuster cardiovascular therapies including Zocor, Crestor, Brilinta, Zetia, Vytorin, Nurtec ODT, Farxiga, and Pradaxa. His unique perspective bridges clinical practice and pharmaceutical leadership, as he continues to see patients while guiding drug development strategy, ensuring that therapeutic innovations remain grounded in real-world clinical needs. Dr. Davidson emphasizes the critical importance of early prevention in cardiovascular health and advocates for greater physician involvement in biopharmaceutical leadership roles. Currently focused on developing innovative treatments for cardiovascular disease and lipid-related conditions, his work at NewAmsterdam Pharma continues to advance the scientific understanding of lipid-lowering therapies with the potential to transform patient outcomes worldwide.
